$CRVO Cashflow Statement | Understand Stock

$CRVO

$2.22 -$0.02 (0.89%) Close

$CRVO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Loss on disposal of property and equipment
Accretion of discount on marketable securities, net
Stock-based compensation expense
Abandonment of in-process research and development intangible asset
Change in deferred income taxes
Amortization of premium and discount on marketable securities
Capital in lieu of executive compensation
Changes in fair value of convertible debt

Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Accounts payable, accrued expenses and other current liabilities
Deferred offering costs
Accounts payable
Accrued expenses and other liabilities
Grant receivable
Net cash used in operating activities

Cash flows from investing activities:
Cash received from sale of property and equipment
Purchase of marketable securities
Maturities of marketable securities
Net cash provided by (used in) investing activities
Net assets assumed in connection with reverse recapitalization

Cash flows from financing activities:
Proceeds from sale of common stock, prefunded warrants and common stock warrants
Sale of common stock under At-the-Market Sales Agreement, net of issuance costs
Open Market Sales Agreement
Total sale of common stock under At-the-Market Sales Agreement, net of issuance costs
Proceeds from the sale of common stock warrants
Payment of offering costs
Proceeds from Warrant Exercises
Proceeds from the sale of preferred stock
Payment of reverse capitalization costs
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of the year
Cash and cash equivalents at end of the year

Supplemental disclosure of non-cash investing and financing activities:
Conversion of convertible notes
Conversion of convertible preferred stock
Unrealized gain on marketable securities
Vesting of restricted stock units
Stock options granted in lieu of cash bonus
Cashless exercise of pre-funded warrants
Deferred offering costs in accounts payable

Comments